Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06456515
Other study ID # F-IRB-SOP-00710
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date March 2026

Study information

Verified date May 2024
Source The First People's Hospital of Changzhou
Contact Wenwei Hu
Phone 13912330886
Email ei1979@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this clinical trial is to find out whether Regorafenib and Sintilimab in combination with electroacupuncture works in treating participants with microsatellite stable (MSS) advanced colorectal cancer who have failed one or more second-line standard chemotherapy regimens. It will also learn about the efficacy and safety of the combination therapy. The main questions the trial aims to answer are: Does combination therapy reduce the overall survival time ? What medical problems do people have when they take combination therapy? Participants will Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date March 2026
Est. primary completion date March 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Fullly knowledge of the study and voluntarily sign the informed consent; 2. Histologically and/or cytologically confirmed metastatic colorectal adenocarcinoma (Stage IV) with microsatellite stable (MSS)* confirmed by PCR or NGS; 3. Receive at least two lines of standard chemotherapy in the past and have failed. 4. No systemic chemotherapy or antitumor therapy such as radiotherapy, immunotherapy, biological or hormonal therapy in the past 4 weeks; and have never received VEGFR inhibitors 5. Willing to receive electroacupuncture; 6. Aged 18-75 years old (including 18 years old and 75 years old); 7. Weighing more than 40 kg (including 40 kg); 8. Able to take oral medication. 9. Patients with adequate organ function at the time of enrollment are defined as follows: Neutrophil count =1500mm3 Platelet count =10.0 × 104/mm3 Hemoglobin (Hb) = 9 g/dL Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =100 U/L (=100 U/L in patients with hepatocellular carcinoma, =250 U/L in patients with liver metastasis) Total bilirubin =1.5 mg /dL Creatinine =1.5 mg /dL Lipase = 80 IU/L Urine Protein: one of the following (if any of the criteria are met, no other test may be performed) (i) Urine Protein (paper test) of 2+ or less (ii) UPC < 3.5 (iii) Urine Protein ? 3500 mg for 24 hour urine protein measurements. mg Prothrombin time (PT)-International Normalized Ratio (INR): = 1.5 (= 3.0 for anticoagulant administration) 10. Eastern Cooperative Oncology Group Physical Performance Score (ECOG PS) = 1 (0-1); 11. Cardiac function evaluation: left ventricular ejection fraction = 50% (echocardiography); 12. Clearly meet the criteria for evaluating the efficacy of solid tumors (e.g., echocardiograms) Measurable lesions that meet the requirements of RECIST 1.1; 13. Expected survival of more than 12 weeks. Exclusion Criteria: Patients will be excluded from the study if any of the following criteria are met. 1. Patients who have received systemic chemotherapy, radiotherapy, surgery, hormonal therapy or immunotherapy <2 weeks prior to enrolment. Immune checkpoint blockade pretreatment is permitted. 2. Patients with a history of regorafenib administration. 3. Patients with uncontrolled hypertension (systolic blood pressure =160 mmHg and diastolic blood pressure =90 mmHg) despite multiple antihypertensive medications; and 4. Patients with acute coronary syndromes (including myocardial infarction and unstable angina) and a history of coronary angioplasty or stenting within 6 months prior to enrolment; 5. Patients with a large pleural effusion or ascites requiring drainage; and 6. Patients with grade = 3 active infection according to NCI CTC AE version 4.03; patients with symptomatic brain metastases; and patients with a history of coronary artery angioplasty or stenting within the previous 6 months. 7. Patients with symptomatic brain metastases; 8. Patients with partial or complete gastrointestinal obstruction; 9. Patients with interstitial lung disease with active signs or symptoms; 10. Patients who test positive for anti-HIV-1 antibody, anti-HIV-2 antibody, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV)* *Patients who test positive for anti-hepatitis B surface (HBs) or anti-hepatitis B core (HBc) antibodies and patients with hepatitis B virus (HBV)-DNA measurements that are greater than the sensitivity of the test will also be excluded. Patients with concurrent autoimmune disease 11. Patients with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease. 12. Patients requiring systemic corticosteroids (excluding those given temporarily for testing, prophylactic administration for allergic reactions, or for the relief of swelling associated with radiotherapy) or immunosuppressive agents, or who have received such therapy <14 days prior to study participation; 13. Patients with a history or finding of class =III congestive heart failure according to the New York Heart Association functional class; 14. Patients with epilepsy requiring pharmacological treatment; 15. Patients with grade 3 or greater bleeding within 4 weeks prior to enrolment. 16. Patients who have undergone major surgery (open heart or caesarean section, etc.), caesarean biopsy, or trauma within 28 days prior to enrolment. the same day of the week prior to the 4-week period may be enrolled (however, in the case of manual anastomosis without bowel resection, this should be within 14 days prior to enrolment); 17. Patients with non-healing wounds, non-healing ulcers or non-healing fractures. 18. Patients with a history of hypersensitivity reaction to any investigational drug, analogue or excipient. 19. Women who are pregnant or breastfeeding or have the potential to become pregnant. 20. Patients with contraindications to electroacupuncture therapy or patients for whom electroacupuncture is contraindicated in accordance with TCM syndromes.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Regorafenib and Sintilimab in combination with electroacupuncture
Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing cycle.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
The First People's Hospital of Changzhou

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival (OS) The time from randomization to death Up to 2 years
Secondary Objective response rate (ORR) The proportion of patients that respond either partially or fully to therapy Up to 2 years
Secondary Progression-free survival (PFS) The time from randomization until first evidence of disease progression or death Up to 2 years
Secondary Disease control rate (DCR) Percentage of patients with advanced cancer whose therapeutic intervention has led to a complete response, partial response, or stable disease Up to 2 years
Secondary Time to progression (TTP) The time from randomization until first evidence of disease progression Up to 2 years
Secondary Health-related quality of life (HRQoL) Assessment of patient quality of life with respect to health status Up to 2 years
Secondary Adverse events (AE) Use the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.
Overall incidence of TEAE;
Incidence of grade 3 or higher AE;
Incidence of SAEs;
Incidence of AEs leading to permanent discontinuation;
Incidence of AEs leading to medication suspension or dose adjustment.
Up to 2 years
Secondary Cancer-related fatigue(CRF) A distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer and/or cancer treatment that is not proportional to recent activity and interferes with usual functioning, use the Revised Piper Fatigue Scale (RPFS) Up to 2 years
Secondary Biomarker Biomarker analysis can be categorized as "non-genetic" (e.g., associated proteins) or "genetically relevant" (e.g., associated RNA or DNA). Up to 2 years
Secondary Cmax Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Blood samples should be collected within 2 hours before electroacupuncture administration and 1 to 4 hours after electroacupuncture by weeks 2 and 3, and 2 hours before electroacupuncture in cycles 4-6
Up to 2 years
Secondary Immune-related adverse event (irAE) Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT03941080 - Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Completed NCT03647839 - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Terminated NCT02316496 - Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study Phase 2
Completed NCT03251612 - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02380443 - AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer Phase 2
Recruiting NCT02149784 - Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients Phase 3
Recruiting NCT01959061 - Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Phase 4
Terminated NCT01668680 - Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma Phase 2
Recruiting NCT05068531 - Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Not yet recruiting NCT04525807 - Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
Completed NCT04482608 - The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Recruiting NCT03193710 - The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved N/A
Recruiting NCT04854213 - PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) N/A
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03144804 - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Phase 2
Completed NCT03142516 - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status Phase 2
Active, not recruiting NCT01910610 - Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Phase 3
Recruiting NCT05759728 - A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2